Study analysis · Cell · 2021
Bone metastases aren't just dead ends—they're cancer 'launching pads' that send new tumors to other organs, and a single epigenetic switch controls it, a new mouse study finds.
In mice, cancer that spreads to bone becomes more aggressive and spreads to other organs, driven by a reversible epigenetic change involving EZH2.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study used mice to see if cancer that spreads to bone can then spread to other organs. It shows this can happen in mice and suggests a possible reason, but it doesn't prove that the same thing happens in people. So we can't say for sure that bone metastases cause further spread in humans.
What’s the bottom line?
In mice, cancer that settled in bone became more aggressive and spread to many organs. This seemed driven by reversible epigenetic changes and EZH2, not just gene mutations. A correction notice exists, so check the errata.
How strong is this study?
The study is well-designed for animal research, using randomization, control groups, and several different methods to check the results. However, it's still in mice, and the researchers weren't blinded, so we should be careful about how much we trust the findings for humans.
60 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availability+25/25
56 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 523 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a preclinical animal study in mice, not a human clinical trial. While randomized controlled experiments in animals can establish causal mechanisms within the animal model, they cannot establish cause-effect relationships in humans due to species differences, artificial metastasis models, and lack of clinical validation.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information were provided in the analyzed text, so the study's COI status cannot be determined.
The provided excerpt includes only the title, abstract, introduction, and part of the results. It lacks author affiliations, funding acknowledgments, and any conflict of interest or competing interests declaration. Full article metadata is needed to properly assess COI and funding.
Key takeaways
- 01
Bone lesions caused secondary metastases in lungs, liver, kidney, brain, and other bones in mice 4–8 weeks after injection.
- 02
Bone lesions gave at least 10-fold higher relative normalized lung tumor burden than direct IV injection.
- 03
In parabiosis, about 20% (roughly 1 in 5) of mice sharing blood with bone-lesion donors had cancer cells in organs, versus 0% with mammary-tumor donors.
- 04
EZH2 inhibitor or knockdown abolished the extra spread.
- 05
No human absolute risk was reported.
- 06
These are mouse experiments, not human risk estimates.
- 07
The 10-fold increase is a relative fold-change in mice.
- 08
The 20% is an absolute proportion in a mouse parabiosis model.
- 09
No baseline human risk, absolute risk increase, or extra cases per 1,000 people can be calculated from this study.
Surprising findings
- Bone lesions from relatively indolent MCF7 breast cancer cells also produced multi-organ metastases, albeit after a longer lag.Even less aggressive cancers can become dangerous once in bone.
- EZH2 inhibition blocked secondary metastasis without affecting primary tumor growth.Challenges the assumption that you need to shrink the primary tumor to stop spread.
- Asymptomatic, small metastases can seed further metastases.Suggests that even undetectable lesions can be dangerous.
Practical takeaways
For researchers: consider targeting EZH2 to prevent secondary metastasis from bone.
Mouse study only; no human data yet. EZH2 inhibitors may have side effects.
medium confidenceFor clinicians: monitor bone metastases for potential spread, even if asymptomatic.
No direct human evidence from this study; correlation only.
low confidenceFor patients: don't assume bone metastasis is the end; ask about monitoring for other organs.
This is preclinical; clinical practice not changed yet.
low confidenceWhy this study matters
Bone: Not a Dead End, But a Launching Pad
In mice, breast and prostate cancer cells that colonized bone produced secondary metastases in lungs, liver, kidney, brain, and other bones 4-8 weeks after injection. When tumor burden was matched, bone lesions generated at least 10-fold higher relative normalized lung tumor burden than direct intravenous injection.
Challenges the long-held view that bone metastasis is a terminal event. Suggests that treating bone metastases might prevent further spread.
The EZH2 Master Switch
Enhanced EZH2 activity in cancer cells mediated the increased stemness and secondary metastasis. Inhibiting EZH2 with a drug or genetic knockdown completely abolished the enhanced metastasis without suppressing primary bone lesion growth in mice.
Identifies a potential drug target to block metastatic spread, not just tumor growth.
Parabiosis Proof: Sharing Blood Shares Cancer
In parabiosis experiments where a mouse with bone lesions shared circulation with a tumor-free mouse, about 20% (absolute proportion) of recipients developed cancer cells in various organs, mostly microscopic, compared to 0% when the donor had a mammary tumor.
Provides strong evidence that bone lesions actively shed cancer cells into the bloodstream.
Epigenetic, Not Genetic: The Change Is Reversible
Bone-entrained cancer cells showed higher ALDH1 and CD44, but these traits were lost after in vitro passage. The same effects occurred in single-cell-derived populations, indicating epigenetic reprogramming, not clonal selection.
Suggests that the aggressive behavior is not permanent and could potentially be reversed.
Human Connection: CD44 Higher in Bone Metastasis Patients
Circulating tumor cells from breast cancer patients with bone metastasis had significantly higher CD44 expression than those with other metastases, providing clinical correlation.
Hints that the mouse findings might translate to humans, though direct proof is lacking.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In mice, cancer that settled in bone became more aggressive and spread to many organs. This seemed driven by reversible epigenetic changes and EZH2, not just gene mutations. A correction notice exists, so check the errata.
Research results
Bone lesions caused secondary metastases in lungs, liver, kidney, brain, and other bones in mice 4–8 weeks after injection. Bone lesions gave at least 10-fold higher relative normalized lung tumor burden than direct IV injection. In parabiosis, about 20% (roughly 1 in 5) of mice sharing blood with bone-lesion donors had cancer cells in organs, versus 0% with mammary-tumor donors. EZH2 inhibitor or knockdown abolished the extra spread. No human absolute risk was reported.
What this means - more context
These are mouse experiments, not human risk estimates. The 10-fold increase is a relative fold-change in mice. The 20% is an absolute proportion in a mouse parabiosis model. No baseline human risk, absolute risk increase, or extra cases per 1,000 people can be calculated from this study.
Test whether the bone microenvironment promotes metastasis-to-metastasis seeding and identify mechanisms, using mouse models of breast and prostate cancer.
NOTE: THIS STUDY HAS CORRECTIONS/ERRATA. Readers should check the correction notices for updated information. In mice, bone lesions from breast/prostate cancer cells produced secondary multi-organ metastases and showed enhanced spread versus orthotopic tumors or lung lesions. The effect was linked to reversible epigenetic reprogramming, stem-like properties, and EZH2 activity. No direct human clinical proof of bone-to-other-organ seeding was provided.
Methods Used
Mouse models (MDA-MB-231, MCF7, AT-3, PC3), intra-iliac artery/intra-femoral injection, parabiosis, evolving CRISPR barcode lineage tracing, organ-entrained single-cell-derived populations, EZH2 inhibitor/knockdown, and patient circulating tumor cell scRNA-seq correlation.
Main Finding
Bone lesions produced multi-organ secondary metastases in mice, typically 4–8 weeks after MDA-MB-231 intra-iliac artery injection. Bone lesions generated at least 10-fold higher normalized lung tumor burden than direct intravenous injection (relative fold-change in mice). In parabiosis, about 20% (absolute proportion) of recipients paired with bone-lesion donors had disseminated tumor cells versus 0% with mammary-fat-pad tumor donors. Bone-entrained cells showed higher ALDH1/CD44 and EZH2 activity; EZH2 inhibition or knockdown abolished enhanced metastasis without suppressing primary growth. Absolute human risk was not reported.
Confidence Level
Moderate for mouse mechanism; multiple independent models and methods support the findings, but there is no direct human causal evidence, barcode parent-child inference is qualitative, and corrections/errata exist.
Study Flags
Red Flags
- •Corrections/errata exist; readers should check correction notices
- •Preclinical mouse models only; no direct clinical evidence in patients
- •Parent-child metastasis relationships from barcodes are qualitative; no human absolute risk reported
Surprising Findings
Bone lesions from relatively indolent MCF7 breast cancer cells also produced multi-organ metastases, albeit after a longer lag.
Even less aggressive cancers can become dangerous once in bone.
Practical Takeaways
For researchers: consider targeting EZH2 to prevent secondary metastasis from bone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 523 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT (Oncology)
Subject
Lower probability
on the GRADE evidence scale
This study used mice to see if cancer that spreads to bone can then spread to other organs. It shows this can happen in mice and suggests a possible reason, but it doesn't prove that the same thing happens in people. So we can't say for sure that bone metastases cause further spread in humans.
Strengths
- Randomized controlled animal experiments
- Multiple independent approaches (parabiosis, evolving barcode, genetic/pharmacologic inhibition)
- Use of both immunodeficient and immunocompetent mouse models
Weaknesses
- Preclinical animal study, not human
- Lack of blinding in animal experiments
- Sample sizes not pre-determined
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In mice, cancer that settled in bone became more aggressive and spread to many organs. This seemed driven by reversible epigenetic changes and EZH2, not just gene mutations. A correction notice exists, so check the errata.
Research results
Bone lesions caused secondary metastases in lungs, liver, kidney, brain, and other bones in mice 4–8 weeks after injection. Bone lesions gave at least 10-fold higher relative normalized lung tumor burden than direct IV injection. In parabiosis, about 20% (roughly 1 in 5) of mice sharing blood with bone-lesion donors had cancer cells in organs, versus 0% with mammary-tumor donors. EZH2 inhibitor or knockdown abolished the extra spread. No human absolute risk was reported.
What this means - more context
These are mouse experiments, not human risk estimates. The 10-fold increase is a relative fold-change in mice. The 20% is an absolute proportion in a mouse parabiosis model. No baseline human risk, absolute risk increase, or extra cases per 1,000 people can be calculated from this study.
Test whether the bone microenvironment promotes metastasis-to-metastasis seeding and identify mechanisms, using mouse models of breast and prostate cancer.
NOTE: THIS STUDY HAS CORRECTIONS/ERRATA. Readers should check the correction notices for updated information. In mice, bone lesions from breast/prostate cancer cells produced secondary multi-organ metastases and showed enhanced spread versus orthotopic tumors or lung lesions. The effect was linked to reversible epigenetic reprogramming, stem-like properties, and EZH2 activity. No direct human clinical proof of bone-to-other-organ seeding was provided.
Methods Used
Mouse models (MDA-MB-231, MCF7, AT-3, PC3), intra-iliac artery/intra-femoral injection, parabiosis, evolving CRISPR barcode lineage tracing, organ-entrained single-cell-derived populations, EZH2 inhibitor/knockdown, and patient circulating tumor cell scRNA-seq correlation.
Main Finding
Bone lesions produced multi-organ secondary metastases in mice, typically 4–8 weeks after MDA-MB-231 intra-iliac artery injection. Bone lesions generated at least 10-fold higher normalized lung tumor burden than direct intravenous injection (relative fold-change in mice). In parabiosis, about 20% (absolute proportion) of recipients paired with bone-lesion donors had disseminated tumor cells versus 0% with mammary-fat-pad tumor donors. Bone-entrained cells showed higher ALDH1/CD44 and EZH2 activity; EZH2 inhibition or knockdown abolished enhanced metastasis without suppressing primary growth. Absolute human risk was not reported.
Confidence Level
Moderate for mouse mechanism; multiple independent models and methods support the findings, but there is no direct human causal evidence, barcode parent-child inference is qualitative, and corrections/errata exist.
Study Flags
Red Flags
- •Corrections/errata exist; readers should check correction notices
- •Preclinical mouse models only; no direct clinical evidence in patients
- •Parent-child metastasis relationships from barcodes are qualitative; no human absolute risk reported
Surprising Findings
Bone lesions from relatively indolent MCF7 breast cancer cells also produced multi-organ metastases, albeit after a longer lag.
Even less aggressive cancers can become dangerous once in bone.
Practical Takeaways
For researchers: consider targeting EZH2 to prevent secondary metastasis from bone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 523 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT (Oncology)
Subject
Lower probability
on the GRADE evidence scale
This study used mice to see if cancer that spreads to bone can then spread to other organs. It shows this can happen in mice and suggests a possible reason, but it doesn't prove that the same thing happens in people. So we can't say for sure that bone metastases cause further spread in humans.
Strengths
- Randomized controlled animal experiments
- Multiple independent approaches (parabiosis, evolving barcode, genetic/pharmacologic inhibition)
- Use of both immunodeficient and immunocompetent mouse models
Weaknesses
- Preclinical animal study, not human
- Lack of blinding in animal experiments
- Sample sizes not pre-determined
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is well-designed for animal research, using randomization, control groups, and several different methods to check the results. However, it's still in mice, and the researchers weren't blinded, so we should be careful about how much we trust the findings for humans.
60 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availability+25/25
56 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 523 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a preclinical animal study in mice, not a human clinical trial. While randomized controlled experiments in animals can establish causal mechanisms within the animal model, they cannot establish cause-effect relationships in humans due to species differences, artificial metastasis models, and lack of clinical validation.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information were provided in the analyzed text, so the study's COI status cannot be determined.
The provided excerpt includes only the title, abstract, introduction, and part of the results. It lacks author affiliations, funding acknowledgments, and any conflict of interest or competing interests declaration. Full article metadata is needed to properly assess COI and funding.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
25 researchersIf this is your work, this is how we attribute it on Fit Body Science. Weijie Zhang is listed as the lead author.